A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer

Jean-Charles Soria,Alex A. Adjei,Rastilav Bahleda,Benjamin Besse,Charles Ferté,David Planchard,Jing Zhou,Joseph A. Ware,Kari Morrissey,Geetha Shankar,Wei Lin,Jennifer L. Schutzman,Grace K. Dy,Harry J.M. Groen

European Journal of Cancer（2017）

引用 26|浏览7

暂无评分

摘要

•Pictilisib is a potent class I pan-PI3K inhibitor.•The pictilisib combination treatments were feasible from a safety perspective.•No drug–drug interactions were observed in the combination treatment regimens.•Encouraging preliminary anti-tumour activity was observed.

查看译文

关键词

Phosphatidylinositol 3-kinase,Non–small cell lung,Bevacizumab,Paclitaxel,Carboplatin,Cisplatin,Pemetrexed,Metastatic NSCLC,Front-line NSCLC,First-line NSCLC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要